Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOGenmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody Share XDenmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOhttps://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/
Novartis buys into bispecific antibodies with Xencor dealAgreement could add to Novartis’ immuno-oncology pipeline. Share XNovartis buys into bispecific antibodies with Xencor dealhttps://pharmaphorum.com/news/novartis-signs-150m-antibody-deal-xencor/